Cargando…
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
BACKGROUND: The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. METH...
Autores principales: | García-Pérez, Javier, González-Pérez, María, Castillo de la Osa, María, Borobia, Alberto M., Castaño, Luis, Bertrán, María Jesús, Campins, Magdalena, Portolés, Antonio, Lora, David, Bermejo, Mercedes, Conde, Patricia, Hernández-Gutierrez, Lourdes, Carcas, Antonio, Arana-Arri, Eunate, Tortajada, Marta, Fuentes, Inmaculada, Ascaso, Ana, García-Morales, María Teresa, Erick de la Torre-Tarazona, Humberto, Arribas, José-Ramón, Imaz-Ayo, Natale, Mellado-Pau, Eugènia, Agustí, Antonia, Pérez-Ingidua, Carla, Gómez de la Cámara, Agustín, Ochando, Jordi, Belda-Iniesta, Cristobal, Frías, Jesús, Alcamí, José, Pérez-Olmeda, Mayte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249304/ https://www.ncbi.nlm.nih.gov/pubmed/35795713 http://dx.doi.org/10.1016/j.eclinm.2022.101529 |
Ejemplares similares
-
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
por: Borobia, Alberto M, et al.
Publicado: (2021) -
No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study
por: Butta, Nora V., et al.
Publicado: (2023) -
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
por: Ascaso-del-Rio, Ana, et al.
Publicado: (2022) -
Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol
por: Monserrat Villatoro, Jaime, et al.
Publicado: (2020) -
T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19
por: Zenarruzabeitia, Olatz, et al.
Publicado: (2021)